References
- Hickman SJ, Ko M, Chaudhry F, Jay WM, Plant GT. Optic neuritis: an update typical and atypical optic neuritis. Neuroophthalmology. 2008;32(5):237–248. doi:https://doi.org/10.1080/01658100802391905.
- Woung L-C, Chung H-C, Jou J-R, Wang K-C, Peng P-H. A comparison of optic neuritis in Asian and in Western countries. Neuroophthalmology. 2011;35(2):65–72. doi:https://doi.org/10.3109/01658107.2011.557851.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi:https://doi.org/10.1212/WNL.0000000000001729.
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:https://doi.org/10.1016/S1474-4422(17)30470-2.
- Wynford-Thomas R. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280–1286. doi:https://doi.org/10.1007/s00415-018-9122-2.
- Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73(11):1297–1307. doi:https://doi.org/10.1001/jamaneurol.2016.2549.
- Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol. 2015;72(2):187–193. doi:https://doi.org/10.1001/jamaneurol.2014.3602.
- de Seze J. Inflammatory optic neuritis: from multiple sclerosis to neuromyelitis optica. Neuroophthalmology. 2013;37(4):141–145. doi:https://doi.org/10.3109/01658107.2013.804232.
- Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014;10(8):447–458. doi:https://doi.org/10.1038/nrneurol.2014.108.
- Zhao G, Chen Q, Huang Y, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018;265(1):33–40. doi:https://doi.org/10.1007/s00415-017-8651-4.
- Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. New Engl J Med. 1992;326(9):581–588. doi:https://doi.org/10.1056/NEJM199202273260901.
- Newman NJ. The Optic Neuritis Treatment Trial. Ophthalmol Res. 2020;127(Supplement):S172–S173. doi:https://doi.org/10.1016/j.ophtha.2019.09.046.
- Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2008;126(7):994–995. doi:https://doi.org/10.1001/archopht.126.7.994.
- Moss HE, Gao W, Balcer LJ, Joslin CE. Association of race/ethnicity with visual outcomes following acute optic neuritis. JAMA Ophthalmol. 2014;132(4):421–427. doi:https://doi.org/10.1001/jamaophthalmol.2013.7995.
- Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109:(12). 1673–1678. doi:https://doi.org/10.1001/archopht.1991.01080120057025.
- Cleary PA, Beck RW, Anderson MM, Kenny DJ, Backlund JY, Gilbert PR. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials. 1993;14(2):123–142. doi:https://doi.org/10.1016/0197-2456(93)90015-6.
- Biousse V, Calvetti O, Drews-Botsch CD, et al. Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci. 2009;276(1–2):69–74. doi:https://doi.org/10.1016/j.jns.2008.08.039.
- Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Soc Sci Med. 2018;210:2–21. doi:https://doi.org/10.1016/j.socscimed.2017.12.005.
- Du Y, Ling Y, Zhou C-X, Song Q-X, Wang D-M, He J-F. Why we should treat idiopathic optic neuritis with high-dose and long-term corticosteroids in China. Med Hypotheses. 2009;72(4):478–479. doi:https://doi.org/10.1016/j.mehy.2008.11.011.
- Ling Y, Du Y, Li K, He J-F. Keeping an eye on optic neuritis studies in mainland China. Neuroophthalmology. 2012;36(3):116–117. doi:https://doi.org/10.3109/01658107.2012.673682.
- Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. doi:https://doi.org/10.1212/NXI.0000000000000572.
- Borchert M, Liu GT, Pineles S, Waldman AT. Pediatric optic neuritis: what is new. J Neuroophthalmol. 2017;37:S14–S22. doi:https://doi.org/10.1097/WNO.0000000000000551.
- Alter M, Good J, Okihiro M. Optic neuritis in Orientals and Caucasians. Neurology. 1973;23(6):631–639. doi:https://doi.org/10.1212/wnl.23.6.631.
- Kurland LT. Descriptive epidemiology of selected neurologic and myopathic disorders with particular reference to a survey in Rochester, Minnesota. J Chronic Dis. 1958;8(4):378–418. doi:https://doi.org/10.1016/0021-9681(58)90002-x.
- Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis: an epidemiologic study. Arch Ophthalmol. 1972;87(2):135–139. doi:https://doi.org/10.1001/archopht.1972.01000020137004.
- Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT. Optic neuritis: a population‐based study in Olrnsted County, Minnesota. Neurology. 1995;45(2):244–250. doi:https://doi.org/10.1212/WNL.45.2.244.
- Hassan MB, Stern C, Flanagan EP, et al. Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol. 2020:Dec:110–114. doi:https://doi.org/10.1016/j.ajo.2020.07.014.
- Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city: part III Results. Acta Neurol Scand. 1966;42:19–74.
- Braithwaite T, Subramanian A, Petzold A, et al. Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease. JAMA Neurol. 2020;77(12):1514–1523. doi:https://doi.org/10.1001/jamaneurol.2020.3502.
- Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, et al. Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012. J Neurol. 2014;261(4):759–767. doi:https://doi.org/10.1007/s00415-014-7266-2.
- Grønning M, Mellgren SI, Schive K. Optic neuritis in the two northernmost counties of Norway. A study of incidence and the prospect of later development of multiple sclerosis. Arctic Med Res. 1989;48:117–121.
- Haller P, Patzold U, Eckert G. Optic Neuritis in Hannover — an Epidemiologic and Serogenetic Study. In H. J. Bauer, S. Poser, G. Ritte (Eds.)., Progress in Multiple Sclerosis Research. Berlin, Heidelberg: Springer; 1980:546–548. doi:https://doi.org/10.1007/978-3-642-67554-6_104.
- Congia S, Vacca MA, Tronci S. Epidemiologic and clinical features of optic neuritis in the 20th and 21st sanitary districts of the Sardinia (Italy). Acta Neurol (Napoli). 1989;11(1):10–14.
- Soelberg K, Jarius S, Skejoe H, Engberg H, Mehlsen JJ, Nilsson AC. A population-based prospective study of optic neuritis. Mult Scler. 2017;23(14):1893–1901. doi:https://doi.org/10.1177/1352458517734070.
- Jin YP, de Pedro-Cuesta J, Söderström M, Stawiarz L, Link H. Incidence of optic neuritis in Stockholm, Sweden 1990-1995: i. Age, sex, birth and ethnic-group related patterns. J Neurol Sci. 1998;159(1):107–114. doi:https://doi.org/10.1016/s0022-510x(98)00141-5.
- Loncarek K, Brajac I, Petricek I, Stalekar H, Cerovski B, Pokupe R. Epidemiology of monosymptomatic optic neuritis in Rijeka County, Croatia: meteorological aspects. Coll Antropol. 2005;29(1):309–313. doi:https://doi.org/10.1007/s00415-014-7266-2.
- Bojić L, Ivanisević M, Sinićić A, et al. The incidence of optic neuritis in Split-Dalmatia county, Croatia. Coll Antropol. 2004;28(1):343–347.
- Wikström J. The epidemiology of optic neuritis in Finland. Acta Neurol Scand. 1975;52(3):196–206. doi:https://doi.org/10.1111/j.1600-0404.1975.tb05774.x.
- Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand. 1983;68(6):371–377. doi:https://doi.org/10.1111/j.1600-0404.1983.tb04846.x.
- Siuko M, Kivelä TT, Setälä K, Tienari PJ. Incidence and mimickers of acute idiopathic optic neuritis: analysis of 291 consecutive patients from Southern Finland. Ophthalmic Epidemiol. 2018;25(5–6):386–391. doi:https://doi.org/10.1080/09286586.2018.1500614.
- Kahana E, Alter M, Feldman S. Optic neuritis in relation to multiple sclerosis. J Neurol. 1976;213(2):87–95. doi:https://doi.org/10.1007/BF00313270.
- Lim SA, Wong WL, Fu E, et al. The incidence of neuro-ophthalmic diseases in Singapore: a prospective study in public hospitals. Ophthalmic Epidemiol. 2009;16(2):65–73. doi:https://doi.org/10.1080/09286580902737516.
- Woung L-C, Lin C-H, Tsai C-Y, Tsai M-T, Jou J-R, Chou P. Optic neuritis among National Health Insurance enrollees in Taiwan, 2000-2004. Neuroepidemiology. 2007;29(3–4):250–254. doi:https://doi.org/10.1159/000112858.
- Lee J-Y, Han J, Yang M, Oh SY. Population-based Incidence of pediatric and adult optic neuritis and the risk of multiple sclerosis. Ophthalmology. 2020;127(3):417–425. doi:https://doi.org/10.1016/j.ophtha.2019.09.032.
- Choi DD, Park M-S, Park K-A. Seven-year nationwide incidence of optic neuritis requiring intravenous methylprednisolone injection in Korean adults. Acta Ophthalmol. 2020;98(4):e523–e525. doi:https://doi.org/10.1111/aos.14326.
- Wakakura M, Ishikawa S, Oono S, et al. [Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)]. Nippon Ganka Gakkai Zasshi. 1995;99(1):93–97.
- Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4–IgG in patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018;136(4):419–422. doi:https://doi.org/10.1001/jamaophthalmol.2017.6757.
- Carnero Contentti E, De Virgiliis M, Hryb JP, et al. Aquaporin-4 serostatus and visual outcomes in clinically isolated acute optic neuritis. J Neuroophthalmol. 2019;39(2):165–169. doi:https://doi.org/10.1097/WNO.0000000000000668.
- Ducloyer J-B, Caignard A, Aidaoui R, et al. MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. Br J Ophthalmol. 2020;104(6):842–845. doi:https://doi.org/10.1136/bjophthalmol-2019-314845.
- Horwitz H, Friis T, Modvig S, et al. Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol. 2014;261(1):98–105. doi:https://doi.org/10.1007/s00415-013-7166-x.
- Siuko M, Tienari PJ, Saastamoinen K-P, et al. Neuromyelitis optica and aquaporin-4 (AQP4) autoantibodies in consecutive optic neuritis patients in Southern Finland. Acta Ophthalmol. 2014;92(4):387–391. doi:https://doi.org/10.1111/aos.12187.
- Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298(1–2):158–162. doi:https://doi.org/10.1016/j.jns.2010.07.011.
- Long Y, Qiu W, Hu X, et al. Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders. Clin Neurol Neurosurg. 2012;114(8):1131–1134. doi:https://doi.org/10.1016/j.clineuro.2012.01.022.
- Yang H, Qiu W, Zhao X, et al. The correlation between aquaporin-4 antibody and the visual function of patients with demyelinating optic neuritis at onset. J Ophthalmol. 2015;2015:672931. doi:https://doi.org/10.1155/2015/672931.
- Zhou H, Zhao S, Yin D, et al. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol. 2016;263(7):1382–1389. doi:https://doi.org/10.1007/s00415-016-8155-7.
- Kang H, Chen T, Li H, Xu Q, Cao S, Wei S. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol. 2017;264(10):2130–2140. doi:https://doi.org/10.1007/s00415-017-8606-9.
- Wang J, Zhou H, Qin L, et al. Optic neuritis in the older Chinese population: a 5-year follow-up study. J Ophthalmol. 2017;2017:3458356. doi:https://doi.org/10.1155/2017/3458356.
- Liu H, Zhou H, Wang J, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225–231. doi:https://doi.org/10.1016/j.jns.2018.11.029.
- Kim KM, Kim US. Aquaporin 4 antibody in the Korean patient with new-onset optic neuritis. Semin Ophthalmol. 2018;33(2):215–218. doi:https://doi.org/10.1080/08820538.2016.1208761.
- Lee Y, Park K-A, Oh SY, Min J-H, Kim BJ. Factors associated with changes in retinal layers following acute optic neuritis: a longitudinal study using optical coherence tomography. J Clin Med. 2020;9(12):3857. doi:https://doi.org/10.3390/jcm9123857.
- Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4):e007766. doi:https://doi.org/10.1136/bmjopen-2015-007766.
- Takagi M, Tanaka K, Suzuki T, Miki A, Nishizawa M, Abe H. Anti-aquaporin-4 antibody-positive optic neuritis. Acta Ophthalmol. 2009;87(5):562–566. doi:https://doi.org/10.1111/j.1755-3768.2008.01259.x.
- Ishikawa H, Kezuka T, Shikishima K, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmol. 2019;126(10):1385–1398. doi:https://doi.org/10.1016/j.ophtha.2019.04.042.
- Etemadifar M, Abbasi M, Salari M, Etemadifar F, Tavakoli H. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome. Mult Scler Relat Disord. 2019;27:127–130. doi:https://doi.org/10.1016/j.msard.2018.10.013.
- Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K. Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis. Neuroophthalmology. 2015;39(5):213–219. doi:https://doi.org/10.3109/01658107.2015.1072726.
- GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:(3). 269–285. doi:https://doi.org/10.1016/S1474-4422(18)30443-5.
- Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neur. 2020;11:501. doi:https://doi.org/10.3389/fneur.2020.00501.
- Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111(6):773–775. doi:https://doi.org/10.1001/archopht.1993.01090060061023.
- Deschamps R, Gueguen A, Lecler A, et al. Acute idiopathic optic neuritis: not always benign. Eur J Neurol. 2018;25(11):1378–1383. doi:https://doi.org/10.1111/ene.13753.
- Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002;360:1953–1962.
- Vanikieti K, Poonyathalang A, Jindahra P, Bouzika P, Rizzo JF, Cestari DM. Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: a comparison between Thai and American-Caucasian cohorts. Mult Scler Relat Disord. 2017;17:87–91. doi:https://doi.org/10.1016/j.msard.2017.07.013.
- Ambika S, Balasubramanian M, Theresa L, Veeraputhiran A, Arjundas D. Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India. Int Ophthalmol. 2015;36(6):801–806. doi:https://doi.org/10.1007/s10792-015-0048-8.
- Hansapinyo L, Vivattanaseth C. Clinical characteristics, treatment outcomes and predictive factors in optic neuritis. Open Ophthalmol J. 2018;12:247–255. doi:https://doi.org/10.2174/1874364101812010247.
- Thongmee W, Padungkiatsagul T, Jindahra P, Khongkhatithum C, Thampratankul L, Vanikieti K. Prognostic factors for visual outcomes following the first episode of NMOSD-related optic neuritis in affected eyes. Clin Ophthalmol. 2020;14:4271–4278. doi:https://doi.org/10.2147/OPTH.S285443.
- Zhao Y, Tan S, Chan TCY, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102(10):1372–1377. doi:https://doi.org/10.1136/bjophthalmol-2017-311177.
- Biotti D, Bonneville F, Tournaire E, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017;264(10):2173–2175. doi:https://doi.org/10.1007/s00415-017-8615-8.
- Ducloyer J-B, Michel L, Wiertlewski S, Lebranchu P. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. Eur J Ophthalmol. 2019;29(2):257–261. doi:https://doi.org/10.1177/1120672118784797.
- Merabtene L, Vignal Clermont C, Deschamps R. [Optic neuropathy in positive anti-MOG antibody syndrome]. J Fr Ophtalmol. 2019;42(10):1100–1110. doi:https://doi.org/10.1016/j.jfo.2019.06.006.
- Shor N, Aboab J, Maillart E, et al. Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. Eur J Neurol. 2020;27(2):384–391. doi:https://doi.org/10.1111/ene.14089.
- Zhou Y, Jia X, Yang H, et al. Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes. Eur J Neurol. 2019;26(1):175–183. doi:https://doi.org/10.1111/ene.13791.
- Lee H-J, Kim B, Waters P, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018;15(1):302. doi:https://doi.org/10.1186/s12974-018-1335-x.
- Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128–3138. doi:https://doi.org/10.1093/brain/awx276.
- Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids. JAMA Neurol. 2018;75(6):690–696. doi:https://doi.org/10.1001/jamaneurol.2018.0024.
- Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–1231. doi:https://doi.org/10.1016/S0140-6736(02)08220-X.
- Petzold A, Braithwaite T, van Oosten BW, et al. Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry. 2020;91(1):9–14. doi:https://doi.org/10.1136/jnnp-2019-321653.
- Akaishi T, Takeshita T, Himori N, et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neur. 2020;11:932. doi:https://doi.org/10.3389/fneur.2020.00932.
- Yassine S, Moreno FRS, Chen JJ, McClelland C. Proceedings of the 42nd annual and first virtual Upper Midwest Neuro-Ophthalmology Group meeting, 24 July 2020. Neuroophthalmology. 2020;44(6):407–412. doi:https://doi.org/10.1080/01658107.2020.1831548.
- Plant GT, Sibtain NA, Thomas D. Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series. Mult Scler Int. 2011;2011:815068. doi:https://doi.org/10.1155/2011/815068.
- Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346–351. doi:https://doi.org/10.1136/jnnp-2017-316286.
- Tradtrantip L, Asavapanumas N, Verkman AS. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin Ther Targets. 2020;24(3):219–229. doi:https://doi.org/10.1080/14728222.2020.1732927.
- Mimura O, Ishikawa H, Kezuka T, et al. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol. 2021;65(1):122–132. doi:https://doi.org/10.1007/s10384-020-00790-9.
- Petzold A. Neuroprotection and visual function after optic neuritis. Curr Opin Neurol. 2017;30(1):67–73. doi:https://doi.org/10.1097/WCO.0000000000000418.
- Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65(1):12–17. doi:https://doi.org/10.1016/j.survophthal.2019.08.001.